AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20153794 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 85
Study 20153794 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 85
Study 18328639 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 90 mg
Number of subjects: 40
Study 18328639 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (90 mg)
Number of subjects: 40
Study 18328639 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine (60 mg)
Number of subjects: 40
Study 18328639 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (100 and 200 mg)
Number of subjects: 40
Study 18328639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15914032 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duty cycle
Number of subjects: 0
Study 15914032 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus 'off' duration
Number of subjects: 0
Study 12701941 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (generic psychological therapy)
Number of subjects: 0
Study 12701941 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants (routinely prescribed)
Number of subjects: 0
Study 10586387 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal (N = 18)
Number of subjects: 57
Study 10586387 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal (N = 20)
Number of subjects: 57
Study 10586387 — intervention group
Group type: COMPARATOR
Intervention: Continuation of caffeine level (N = 18)
Number of subjects: 57
Study 8686349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (3 x 2 tablets of 250 mg)
Number of subjects: 15
Study 8686349 — intervention group
Group type: COMPARATOR
Intervention: Olsalazine (2 x 2 capsules of 250 mg)
Number of subjects: 15
Study 1906745 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 therapy for immunosuppression
Number of subjects: 8
Study 6196852 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 2,200 IU/kg/h
Number of subjects: 33
Study 6196852 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 1,100 IU/kg/h
Number of subjects: 33
Study 6196852 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase 100,000 IU/h
Number of subjects: 33
Study 6196852 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 33
Study 31852124 — intervention group
Group type: EXPERIMENTAL
Intervention: Light vegetarian diet (LVD)
Number of subjects: 184
Study 31852124 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug + diet group
Number of subjects: 184
Study 31852124 — intervention group
Group type: COMPARATOR
Intervention: Placebo + diet group
Number of subjects: 184
Study 31852124 — intervention group
Group type: COMPARATOR
Intervention: Drug group
Number of subjects: 184
Study 31852124 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 184
Study 30027003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10‐mg once daily in the morning (QAM)
Number of subjects: 0
Study 30027003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10‐mg once daily at bedtime (QHS)
Number of subjects: 0
Study 30027003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5‐mg twice daily
Number of subjects: 0
Study 30027003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5‐mg QAM
Number of subjects: 0
Study 30027003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10‐mg QHS
Number of subjects: 0
Study 30027003 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 8‐mg BID
Number of subjects: 0
Study 30027003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30027003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (all groups)
Number of subjects: 0
Study 30027003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (all groups in study 1)
Number of subjects: 0
Study 26778151 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA contact lenses
Number of subjects: 30
Study 26778151 — intervention group
Group type: EXPERIMENTAL
Intervention: SiHy contact lenses
Number of subjects: 30
Study 25081694 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta glucan (two 10-mg capsules daily for 21 days)
Number of subjects: 30
Study 25081694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules daily for 21 days)
Number of subjects: 30
Study 23137731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 791
Study 19434781 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapies targeting immune-mediated disease mechanisms
Number of subjects: 0
Study 19434781 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapies targeting distinct cell types and mechanisms
Number of subjects: 0
Study 17845742 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg PO
Number of subjects: 1599
Study 17845742 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg PO
Number of subjects: 1599
Study 17845742 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg IV
Number of subjects: 1599
Study 14998579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine tablets with pH 4.5 acetate buffer containing 0.05% sodium dodecyl sulfate (SDS)
Number of subjects: 0
Study 14998579 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine tablets with pH 4.5 acetate buffer containing 0.3% SDS
Number of subjects: 0
Study 14998579 — intervention group
Group type: EXPERIMENTAL
Intervention: Two brands of nimodipine tablets
Number of subjects: 0
Study 11591558 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (10 mg)
Number of subjects: 9
Study 11591558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9498433 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine (dideoxycytidine) monotherapy
Number of subjects: 38
Study 7748646 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of brief screening instruments for dementia
Number of subjects: 0
Study 7748646 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of brief screening instruments for depression
Number of subjects: 0
Study 7748646 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of brief screening instruments for dementia and depression
Number of subjects: 0
Study 7748646 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgement alone
Number of subjects: 0
Study 7748646 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking screening
Number of subjects: 0
Study 2927306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (limited ROM 120 degrees to 60 degrees of knee flexion)
Number of subjects: 59
Study 2927306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (limited ROM 60 degrees to 0 degrees of knee flexion)
Number of subjects: 59
Study 2927306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group AB (full ROM)
Number of subjects: 59
Study 2927306 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 59
Study 30553026 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise intensity group (MG)
Number of subjects: 34
Study 30553026 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 34
Study 26141208 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 165
Study 26141208 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine plus carboplatin)
Number of subjects: 165
Study 26141208 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 165
Study 26141208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of EGFR-TKI and chemotherapy
Number of subjects: 165
Study 26141208 — intervention group
Group type: EXPERIMENTAL
Intervention: No post-study treatments
Number of subjects: 165
Study 23258572 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445
Study 23258572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3445
Study 20681813 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal periosteal pedicle (MPP) graft as an autogenous guided tissue membrane
Number of subjects: 15
Study 20681813 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 15
Study 19958868 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V
Number of subjects: 1002
Study 16162829 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulus (sharp probe)
Number of subjects: 0
Study 16162829 — intervention group
Group type: COMPARATOR
Intervention: Nonpainful stimulus (blunt probe)
Number of subjects: 0
Study 16162829 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatially congruent position of rubber hand
Number of subjects: 0
Study 16162829 — intervention group
Group type: COMPARATOR
Intervention: Spatially incongruent position of rubber hand
Number of subjects: 0
Study 16162829 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational-affective coding areas (mid-cingulate BA24 and anterior insula)
Number of subjects: 0
Study 16162829 — intervention group
Group type: COMPARATOR
Intervention: Premotor areas
Number of subjects: 0
Study 15478384 — intervention group
Group type: EXPERIMENTAL
Intervention: NebuChamber (200 microg of budesonide twice daily)
Number of subjects: 30
Study 15478384 — intervention group
Group type: COMPARATOR
Intervention: AeroChamber (200 microg of budesonide twice daily)
Number of subjects: 30
Study 15478384 — intervention group
Group type: EXPERIMENTAL
Intervention: NebuChamber
Number of subjects: 30
Study 15478384 — intervention group
Group type: COMPARATOR
Intervention: AeroChamber
Number of subjects: 30
Study 11137829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 40 mg
Number of subjects: 646
Study 11137829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study 9537937 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (INR 2 to 3)
Number of subjects: 382
Study 9537937 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR 1.2 to 1.5) plus aspirin (325 mg/d)
Number of subjects: 382
Study 9537937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (low-intensity warfarin plus aspirin)
Number of subjects: 382
Study 9537937 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex aortic plaque
Number of subjects: 382
Study 7841756 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxin Sutong (NXST)
Number of subjects: 41
Study 7841756 — intervention group
Group type: COMPARATOR
Intervention: Ligustrazine (LT)
Number of subjects: 41
Study 3372408 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive loading (RES)
Number of subjects: 9
Study 3372408 — intervention group
Group type: COMPARATOR
Intervention: Sinusoidal pressure loading (SIN)
Number of subjects: 9
Study 29649372 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts from mandibular symphysis
Number of subjects: 20
Study 29649372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone graft associated with platelet-rich plasma (PRP)
Number of subjects: 20
Study 29649372 — intervention group
Group type: COMPARATOR
Intervention: Bovine bone graft associated with PRP
Number of subjects: 20
Study 29077990 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (three sessions weekly) plus compression therapy
Number of subjects: 39
Study 29077990 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy only
Number of subjects: 39
Study 26647766 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment group (STG)
Number of subjects: 142
Study 26647766 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 142
Study 25017268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received explanatory pamphlet and letter to primary care physician)
Number of subjects: 99
Study 25017268 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional materials)
Number of subjects: 99
Study 22129852 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300 g/d)
Number of subjects: 64
Study 22129852 — intervention group
Group type: COMPARATOR
Intervention: Conventional yogurt (300 g/d)
Number of subjects: 64
Study 19900577 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention (12-minute intervention video)
Number of subjects: 968
Study 19900577 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 968
Study 17442229 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor antagonists (ARA)
Number of subjects: 0
Study 17442229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified blood pressure control and metabolic control in diabetes
Number of subjects: 0
Study 17442229 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention before progressive glomerulosclerosis
Number of subjects: 0
Study 15536162 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily)
Number of subjects: 21
Study 15536162 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily)
Number of subjects: 21
Study 12221387 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral health care (POHC)
Number of subjects: 141
Study 12221387 — intervention group
Group type: COMPARATOR
Intervention: Non-POHC
Number of subjects: 141
Study 10721042 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan 6 g per day
Number of subjects: 37
Study 10721042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7593878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 0
Study 7593878 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study 7593878 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus clinical management (IMI-CM)
Number of subjects: 0
Study 7593878 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus clinical management (PLA-CM)
Number of subjects: 0
Study 1691134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytosine arabinoside (Ara-C) (1 g/m2 i.v. q 12 h days 1-6) and amsacrine (m-AMSA) (120 mg/m2 i.v. days 5-7)
Number of subjects: 34
Study 1691134 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (3 g/m2 i.v. q 12 h days 1-4) and m-AMSA (120 mg/m2 i.v. day 5) for consolidation
Number of subjects: 34
Study 1691134 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 34
Study 6154272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 232
Study 6154272 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 232
Study 31096977 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities (SHHC) program, a six-month twice-weekly experiential learning lifestyle program focused on diet and physical activity (n=101)
Number of subjects: 194
Study 31096977 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities (SHHC) program
Number of subjects: 194
Study 31096977 — intervention group
Group type: COMPARATOR
Intervention: Control program (monthly healthy lifestyle education-only)
Number of subjects: 194
Study 28666848 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol 25 mcg/kg/h + lidocaine 1 mg/kg/h
Number of subjects: 40
Study 28666848 — intervention group
Group type: COMPARATOR
Intervention: propofol 50 mcg/kg/h
Number of subjects: 40
Study 26511605 — intervention group
Group type: EXPERIMENTAL
Intervention: EPICENTER care (multi-component treatment package including cognitive behavioral therapy, family psychoeducation, and metacognitive remediation)
Number of subjects: 68
Study 26511605 — intervention group
Group type: EXPERIMENTAL
Intervention: EPICENTER care
Number of subjects: 68
Study 24453092 — intervention group
Group type: EXPERIMENTAL
Intervention: Water rinse
Number of subjects: 11
Study 24453092 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleaner mouthwash
Number of subjects: 11
Study 24453092 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk rinse
Number of subjects: 11
Study 24453092 — intervention group
Group type: COMPARATOR
Intervention: Passive smoking
Number of subjects: 11
Study 23227811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella tablets during the summer camp
Number of subjects: 10
Study 23227811 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets during the spring camp
Number of subjects: 10
Study 21059322 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised, non-personalised dietary and lifestyle advice
Number of subjects: 154
Study 21059322 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised dietary and lifestyle advice, with reinforcement
Number of subjects: 154
Study 21059322 — intervention group
Group type: COMPARATOR
Intervention: Prescription of laxatives (standard care control arm)
Number of subjects: 154
Study 18197315 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 3% via Injex
Number of subjects: 32
Study 18197315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with epinephrine 1:80,000 via Injex
Number of subjects: 32
Study 18197315 — intervention group
Group type: COMPARATOR
Intervention: Needle injection technique
Number of subjects: 32
Study 15522983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist involvement in treatment
Number of subjects: 235
Study 15522983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist involvement)
Number of subjects: 235
Study 12152676 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral vitamin K
Number of subjects: 100
Study 12152676 — intervention group
Group type: COMPARATOR
Intervention: Withholding acenocoumarol (Control)
Number of subjects: 100
Study 9829441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg b.i.d.
Number of subjects: 2180
Study 9829441 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg b.i.d.
Number of subjects: 2180
Study 8131017 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel (10 ml intraurethrally)
Number of subjects: 138
Study 8131017 — intervention group
Group type: COMPARATOR
Intervention: Plain lubricating gel (10 ml)
Number of subjects: 138
Study 2488674 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 23
Study 2488674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methadone
Number of subjects: 23
Study 88708 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (0.06 mg/kg/dose)
Number of subjects: 120
Study 88708 — intervention group
Group type: COMPARATOR
Intervention: Etilefrin
Number of subjects: 120
Study 31177099 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP plus bimekizumab (240 mg loading dose then 120 mg Q2W)
Number of subjects: 79
Study 31177099 — intervention group
Group type: COMPARATOR
Intervention: CZP plus placebo
Number of subjects: 79
Study 27769783 — intervention group
Group type: EXPERIMENTAL
Intervention: High n‐3/n‐6 PUFAs ratio (3rd vs. 2nd tertile) in Rotterdam Study
Number of subjects: 2073
Study 27769783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SFA/PUFA ratio (1st vs. 2nd tertile) in Rotterdam Study
Number of subjects: 2073
Study 27769783 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher n‐3/n‐6 PUFAs ratio (3rd vs. 2nd tertile) in Rotterdam Study without chronic disease
Number of subjects: 2073
Study 27769783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat composition (n‐3/n‐6 PUFAs ratio and SFA/PUFAs ratio)
Number of subjects: 2073
Study 27769783 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of chronic disease
Number of subjects: 2073
Study 24895062 — intervention group
Group type: EXPERIMENTAL
Intervention: Iosimenol 340 (0.5, 1.5 or 3.0 mL/kg)
Number of subjects: 24
Study 24895062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 24
Study 23642948 — intervention group
Group type: EXPERIMENTAL
Intervention: ProstateEZE Max (herbal preparation)
Number of subjects: 57
Study 23642948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 22121860 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Case Management (OCM)
Number of subjects: 100
Study 22121860 — intervention group
Group type: COMPARATOR
Intervention: Routine Case Management (RCM)
Number of subjects: 100
Study 19705518 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 g daily for 8 weeks)
Number of subjects: 85
Study 19705518 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg daily for 8 weeks)
Number of subjects: 85
Study 19705518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both omega-3 fatty acids and CoQ
Number of subjects: 85
Study 19705518 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 g daily for 8 weeks)
Number of subjects: 85
Study 19543733 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated cine trueFISP MR sequence
Number of subjects: 26
Study 15214098 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (weekly sessions)
Number of subjects: 48
Study 15214098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminiscence intervention)
Number of subjects: 48
Study 12185399 — intervention group
Group type: EXPERIMENTAL
Intervention: TRP-free amino acid mixture
Number of subjects: 0
Study 12185399 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced amino acid drinks (Control)
Number of subjects: 0
Study 9568182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and/or radiation
Number of subjects: 137
Study 8600700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (50 mg, orally t.i.d with food)
Number of subjects: 40
Study 8600700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2634614 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms L-T3 (Thyrotardin)
Number of subjects: 50
Study 2634614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 186223 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee (1, 2, and 4-cup equivalents)
Number of subjects: 18